###begin article-title 0
The G-Quadruplex Ligand Telomestatin Impairs Binding of Topoisomerase IIIalpha to G-Quadruplex-Forming Oligonucleotides and Uncaps Telomeres in ALT Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: JFR. Performed the experiments: NTS LG AS CT. Analyzed the data: NTS LG AS CT. Contributed reagents/materials/analysis tools: KSy. Wrote the paper: CT JFR.
###end p 1
###begin p 2
In Alternative Lengthening of Telomeres (ALT) cell lines, specific nuclear bodies called APBs (ALT-associated PML bodies) concentrate telomeric DNA, shelterin components and recombination factors associated with telomere recombination. Topoisomerase IIIalpha (Topo III) is an essential telomeric-associated factor in ALT cells. We show here that the binding of Topo III to telomeric G-overhang is modulated by G-quadruplex formation. Topo III binding to G-quadruplex-forming oligonucleotides was strongly inhibited by telomestatin, a potent and specific G-quadruplex ligand. In ALT cells, telomestatin treatment resulted in the depletion of the Topo III/BLM/TRF2 complex and the disruption of APBs and led to the segregation of PML, shelterin components and Topo III. Interestingly, a DNA damage response was observed at telomeres in telomestatin-treated cells. These data indicate the importance of G-quadruplex stabilization during telomere maintenance in ALT cells. The function of TRF2/Topo III/BLM in the resolution of replication intermediates at telomeres is discussed.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 104 110 104 110 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTAGGG</named-content>
###xml 312 315 312 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Palm1">[1]</xref>
###xml 492 495 492 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-McEachern1">[2]</xref>
###xml 691 697 691 697 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTAGGG</named-content>
###xml 794 797 794 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-McEachern1">[2]</xref>
###xml 926 929 926 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Cesare1">[3]</xref>
###xml 1201 1204 1201 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Cesare1">[3]</xref>
In vertebrates, the telomeres that cap chromosome ends are composed of tandem repeats of the sequence d(TTAGGG)n with a 3' single-stranded extension (G-overhang) associated with six protein factors (TRF1, TRF2, RAP1, TIN2, TPP1 and POT1) that form a protecting complex (shelterin) essential for genome stability [1]. Telomeres shorten at each round of cell division and cellular mechanisms that counteract this loss confer indefinite proliferation potential characteristic of cancerous cells [2]. Two mechanisms have been reported in the maintenance of telomere length. The first requires a specialized enzyme, called telomerase, which is able to copy, as a reverse transcriptase, the short TTAGGG motif at the 3' end of telomeres; the activity of telomerase is tightly controlled by shelterin [2]. The second mechanism involves recombination between telomeres, a mechanism known as Alternative Lengthening of Telomeres (ALT) [3]. ALT cells are characterized by the absence of telomerase activity, heterogeneous telomere length and the presence of nuclear foci termed ALT-associated PML bodies (APBs) that contain telomeric DNA, telomeric proteins TRF1 and TRF2, and DNA recombination/repair proteins [3].
###end p 4
###begin p 5
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 355 358 355 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Huppert1">[4]</xref>
###xml 571 574 571 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Monchaud1">[5]</xref>
###xml 638 641 638 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Sun1">[6]</xref>
###xml 747 750 747 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Monchaud1">[5]</xref>
###xml 922 925 922 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Lavelle1">[7]</xref>
###xml 927 930 927 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Riou1">[8]</xref>
###xml 1079 1082 1079 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Riou2">[9]</xref>
###xml 1083 1087 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-DeCian1">[11]</xref>
In vitro, DNA oligonucleotides composed of the G-overhang DNA sequence may adopt a four-stranded structure called a G-quadruplex. Both direct and indirect evidence suggests that G-quadruplexes are also present in eukaryotic cells and that formation of this structure must be tightly regulated to allow DNA replication and cell division (for a review, see [4]). The binding of specific ligands to the telomeric G-quadruplex is a strategy to alter telomere functions and to inhibit cell growth. A number of G-quadruplex ligands have been synthesized during the last decade [5]. These compounds were initially derived from DNA intercalators [6] and now present selective binding properties to G-quadruplexes relative to duplex or single-stranded DNA [5]. The initial therapeutic rationale for use of these compounds in treatment of cancer was that inhibition of telomerase activity would inhibit unchecked cell proliferation [7], [8], but several pieces of evidence suggest that these ligands must be considered as telomere targeting agents rather than simple telomerase inhibitors [9]-[11].
###end p 5
###begin p 6
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Rosu1">[12]</xref>
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Shinya1">[14]</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-DeCian2">[15]</xref>
###xml 531 534 531 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Riou1">[8]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Kim1">[13]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gowan1">[16]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Pennarun1">[17]</xref>
The natural product telomestatin, is one of the most potent and selective G-quadruplex binding small molecules known [12]-[14]. Treatment with telomestatin impairs telomere replication and provokes the release of POT1 and TRF2 from telomeres, which results in loss of single- and double-stranded telomeric DNA and inhibits growth of tumor cells [15]. However, little is known about the effect of this compound or other G-quadruplex ligands on telomerase-negative ALT cell lines, except that telomestatin inhibits cell proliferation[8], [13], [16], [17].
###end p 6
###begin p 7
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Li1">[18]</xref>
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-LillardWetherell1">[19]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Yeager1">[21]</xref>
###xml 501 505 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Mankouri1">[22]</xref>
###xml 507 511 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Liu1">[23]</xref>
###xml 625 633 621 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 633 637 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wu1">[24]</xref>
###xml 675 679 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wu2">[25]</xref>
###xml 680 684 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Chen1">[27]</xref>
###xml 754 758 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Singh1">[28]</xref>
###xml 760 764 756 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Xu1">[29]</xref>
###xml 901 905 897 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Ababou1">[30]</xref>
###xml 906 910 902 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wang1">[32]</xref>
###xml 1109 1113 1101 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Rao1">[33]</xref>
G-quadruplex ligands also inhibit in vitro the activity of RecQ helicases WRN and BLM [18]. These helicases are associated with APBs in ALT cells and interact with shelterin components [19]-[21]. BLM is known to interact with Topoisomerase IIIalpha (Topo III) and two other proteins with OB-fold domains, RMI1 and RMI2, to form a RTR complex (RecQ/Topo III/RMI) essential to maintenance of genome stability through its function in the resolution of recombination intermediates (for recent reviews see [22], [23]). In this complex, Topo III and BLM cooperate to convert double Holliday junctions (DHJ) to decatenated products in vitro[24]. RMI1 guides the binding of Topo III [25]-[27] and RMI2 regulates other protein-protein interactions in the complex [28], [29]. The Topo III/BLM complex may function as a repair complex in response to replication defects and may restart stalled replication forks [30]-[32]. Following camptothecin treatment, a phosphorylated form of BLM dissociates from the Topo III/BLM complex at its PML storage sites and accumulates with gamma-H2AX at damage sites during replication [33].
###end p 7
###begin p 8
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wang2">[34]</xref>
###xml 188 196 188 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Chen1">[27]</xref>
###xml 433 440 433 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Changela1">[35]</xref>
###xml 433 440 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Topo III belongs to the Type IA DNA topoisomerase subfamily, which is conserved among different organisms; it removes highly negative supercoils where single-stranded DNA is exposed [34]. In vitro this access can be provided by altering the secondary structure of the substrate using hyper-negative supercoiling or by the addition of single-stranded binding protein (RPA, RMI1) to assist Topo III binding [27]. Structural studies of E. coli Topo III revealed that the protein first recognizes the presence of single-stranded DNA through a specific DNA binding region and then induces protein rearrangements that activate the tyrosine catalytic region [35]. This ensures the recognition of the correct type of DNA by the active site and explains the requirement for cofactors to generate single-stranded DNA.
###end p 8
###begin p 9
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gilson1">[36]</xref>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Amiard1">[37]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Tsai1">[38]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 835 839 835 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
Due to the diversity of complex structures that may form at telomere ends during fork progression, there is a requirement for factors that modulate topology, t-loop formation and resolution [36], [37]. Among these factors, Topo III is an essential telomeric-associated component in ALT cells [38], [39]. Topo III interacts with telomeric DNA and forms a complex with TRF2 and BLM at telomeres in ALT cells [39]. Inhibition of Topo III expression by siRNA reduced ALT cell survival, but did not affect telomerase positive cell lines. Moreover, repression of Topo III expression in ALT cells induced telomere uncapping associated with reduced levels of TRF2 and BLM proteins [39]. This data suggested that the Topo III/BLM/TRF2 complex plays a role in the resolution of topological intermediates that arise during telomere recombination [39].
###end p 9
###begin p 10
To examine whether Topo III binding at telomeric sequences and its localization at APBs is modulated by G-quadruplex formation, we have used the selective G-quadruplex ligand telomestatin. We found that Topo III binding is strongly inhibited by stabilization of G-quadruplex structures and that this ligand induces the disruption of APBs in ALT cells. This effect mimics the depletion of Topo III by RNA interference as it induces the depletion of the Topo III/BLM/TRF2 complex and results in telomere uncapping as evidenced by DNA damage at telomeres. We suggest that telomere maintenance in ALT cells may be particularly sensitive to G-quadruplex formation due to the need for the Topo III/BLM/TRF2 complex to resolve or modulate intermediate recombination/replication structures at telomeres.
###end p 10
###begin title 11
Materials and Methods
###end title 11
###begin title 12
Topo III and POT1 binding assays
###end title 12
###begin p 13
###xml 73 77 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Goulaouic1">[40]</xref>
Topo IIIalpha was purified according to a previously published procedure [40]. Purified recombinant hPOT1, prepared after baculovirus expression, was a generous gift from Dr. D. Gomez (Institut de Pharmacologie et de Biologie Structurale, Toulouse, France).
###end p 13
###begin p 14
The oligonucleotides used in the study were:
###end p 14
###begin p 15
###xml 5 32 5 32 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGTTAGGGTTAGGGTTAGGG-3&#8242;</named-content>
21G: 5'-GGGTTAGGGTTAGGGTTAGGG-3'
###end p 15
###begin p 16
###xml 9 36 9 36 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCTTACGGTTAGCGTTAGGG-3&#8242;</named-content>
21G mu3: 5'-GGCTTACGGTTAGCGTTAGGG-3'
###end p 16
###begin p 17
###xml 6 38 6 38 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTAGGGTTAGGGTTAGGGTTAGGGTT-3&#8242;</named-content>
Wt26: 5'-TTAGGGTTAGGGTTAGGGTTAGGGTT-3'
###end p 17
###begin p 18
###xml 9 37 9 37 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAGGGTGGGGAGGGTGGGGAAG-3&#8242;</named-content>
Pu22myc: 5'-GAGGGTGGGGAGGGTGGGGAAG-3'
###end p 18
###begin p 19
###xml 8 36 8 36 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAGGGTGAAGAGGGTGGGGAAG-3&#8242;</named-content>
Pu22mu: 5'-GAGGGTGAAGAGGGTGGGGAAG-3'
###end p 19
###begin p 20
###xml 5 35 5 35 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCCTAACCCTAACCCTAACCCTAA-3&#8242;</named-content>
24C: 5'-CCCTAACCCTAACCCTAACCCTAA-3'
###end p 20
###begin p 21
###xml 6 33 6 33 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCAGCTCTGCTTTGCATCTTT-3&#8242;</named-content>
S310: 5'-CCAGCTCTGCTTTGCATCTTT-3'
###end p 21
###begin p 22
###xml 57 59 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Oligonucleotides were labelled at the 5' end with [gamma-32P]-ATP using T4 Polynucleotide Kinase (New England BioLabs(R)).
###end p 22
###begin p 23
###xml 1162 1163 1150 1151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
Electrophoretic mobility shift assays using Topo III or hPOT1 were performed in 10 microL of the following solution: 50 mM HEPES (pH 7.9), 100 mM NaCl, 0.1 mM EDTA, 4% w/v sucrose, 2% v/v glycerol, 0.1 mg/mL BSA, 0.02% w/v bromophenol blue, 20 nM labelled oligonucleotide and Topo III (50 nM) or hPOT1 (30 nM). For competition assays, the indicated concentrations of unlabelled oligonucleotides (1, 3, 10, 30, 100, 300, or 1000 nM) were added to the reaction mixture. For binding inhibition assays, the indicated concentrations of telomestatin were added in a volume of 1 microL. Telomestatin was prepared at 5 mM in 1:1 DMSO/MetOH and was dissolved to 100 microM in DMSO and further with water. The reaction mixture was incubated at room temperature for 30 min. Each individual mixture was separated immediately by electrophoresis on 1% agarose gels in 0.5X Tris-Borate-EDTA buffer. The gels were run at 80 V for 45 min, dried on Whatman DE81 paper, and visualized by a phosporimager (Typhoon 9210, Amersham). Data was analyzed using ImageQuant software (Amersham) and results were expressed as the ratio between the initial fraction of DNA bound to Topo III (f0) and the fraction of DNA bound to Topo III in the presence of the competitor (f) as a function of the competitor concentration in abscissa. Values correspond to the mean value of three independent experiments +/- SD.
###end p 23
###begin title 24
Cell culture
###end title 24
###begin p 25
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 222 228 <span type="species:ncbi:9913">bovine</span>
The MRC5-V1/YFP-Topo III cell line is a stable clone of the ALT cell line MRC5-V1 transfected with YFP-Topo III [39] and was grown in Dulbecco's modified Eagle's medium (GIBCO/Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS; Invitrogen), 10 mM L-glutamine, and 400 microg/mL of geneticin. After transfection, cells were selected for 15 days with 400 microg/mL geneticin and cultures were sorted by FACS analysis and further grown in the presence of 400 microg/mL of geneticin.
###end p 25
###begin title 26
Antibodies
###end title 26
###begin p 27
###xml 793 797 782 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Douarre1">[41]</xref>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
###xml 295 300 <span type="species:ncbi:10090">mouse</span>
###xml 337 341 <span type="species:ncbi:9925">goat</span>
###xml 407 413 <span type="species:ncbi:9986">rabbit</span>
###xml 489 493 <span type="species:ncbi:9925">goat</span>
###xml 499 505 <span type="species:ncbi:9986">rabbit</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
###xml 564 570 <span type="species:ncbi:9793">donkey</span>
###xml 576 580 <span type="species:ncbi:9925">goat</span>
###xml 641 645 <span type="species:ncbi:9925">goat</span>
###xml 651 656 <span type="species:ncbi:10090">mouse</span>
###xml 694 698 <span type="species:ncbi:9925">goat</span>
###xml 704 710 <span type="species:ncbi:9986">rabbit</span>
Primary antibodies used in this work were raised against PML (PG-M3, mouse, sc-966 Santa Cruz Biotechnology), TRF2 (4A794, mouse, Upstate Biotechnology), BLM (C18, sc-7790 Santa Cruz Biotechnology), beta-actin (clone AC-15, mouse, Sigma), active caspase-3 (IMG-144, mouse, Imgenex), gamma-H2AX (mouse, Upstate Biotechnology), TRF1 (C19, goat, sc-1977 Santa Cruz Biotechnology), and Topo IIIalpha (clone D6, rabbit (Wu et al., 2000)). Secondary antibodies used for western experiments were goat anti-rabbit and anti-mouse HRP conjugates (Upstate Biotechnology) and donkey anti-goat HRP conjugates (Abcam). For immunofluorescence experiments, goat anti-mouse Alexa fluor 488 and 568 as well as a goat anti-rabbit Alexa fluor 568 (Invitrogen) were used. Immunoblotting was performed according to [41].
###end p 27
###begin title 28
G-overhang hybridization assays
###end title 28
###begin p 29
###xml 132 133 132 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez1">[42]</xref>
The nondenaturing hybridization assay to detect the 3' telomeric G-overhang was performed as described previously using the (AATCCC)4 oligonucleotide [42].
###end p 29
###begin title 30
Immunofluorescence
###end title 30
###begin p 31
###xml 227 228 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were plated in 6-well culture plates on glass coverslips. After drug treatment, cells were washed with 1X PBS (pH 7.2), fixed with 4% paraformaldehyde, and permeabilized with 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose and 0.5% v/v Triton X-100 for 15 min at room temperature. Cells were then washed twice with PBS (pH 7.2). Cells were blocked with 1% BSA in 1X PBS for 1 hour and incubated with primary antibodies for 1 hour to 2 hours at room temperature. After washing with 1X PBS proteins of interest were detected by incubation for 30 min with fluorescently label secondary antibodies, then washed with 1X PBS. The nuclear DNA was stained with 0.1 microg/mL DAPI in PBS (pH 7.2) for 4 min. Cells were mounted in Shandon Immu-Mount medium (Thermo Scientific). Samples were observed with a DMR Leica microscope and images were captured with a Cool Snap HQ camera (Roper Scientific) controlled by Metamorph software (Roper Scientific). Final images are composed of arithmetic stacks of 15-25 deconvolued images, each 0.2 microM in z-step. Stacks of 15-30 images (16 bit grayscale) were acquired with a z-step of 0.2 microm with low illumination intensity. For the quantification of co-localizations, 50 nuclei were analyzed and results represent the mean +/- SD relative to YFP-Topo III or TRF1 foci, as indicated.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Topo III binds to G-quadruplex but prefers single-stranded structures
###end title 33
###begin p 34
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Lemarteleur1">[43]</xref>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez2">[44]</xref>
###xml 861 882 861 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 907 916 907 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g001">Figure 1A</xref>
###xml 1390 1399 1390 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g001">Figure 1B</xref>
###xml 1408 1410 1408 1410 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1576 1585 1576 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g001">Figure 1B</xref>
Purified recombinant Topo III interacts with single-stranded DNA, including the telomeric G-overhang sequence [39]. Since telomeric G-overhang is prone to form G-quadruplexes, we have examined whether the presence of guanines repeats influences the DNA binding of Topo III. A direct binding assay for Topo III to the telomeric G-overhang or to a mutated sequence unable to form G-quadruplex indicated that Topo III has a slight preference for single-stranded DNA that cannot fold into a G-quadruplex (result not shown). To quantify differences in binding, we have performed competition experiments with radioactively labeled single-stranded oligonucleotides (21G, S310 and 24C), unlabeled DNA oligonucleotides able to form G-quadruplex (21G, Pu22myc) or unable to form G-quadruplex (21Gmu, Pu22mu) [43], [44]. The sequences of oligonucleotides are given in the Materials and Methods section. As an example, Figure 1A presents the analysis of the competition for Topo III binding to oligonucleotide 24C with either the G-quadruplex forming Pu22myc or its mutant Pu22mu, which is unable to fold into G-quadruplex. A 3-fold higher concentration of Pu22myc than Pu22mu was needed to inhibit Topo III binding to single-stranded oligonucleotide 24C. Similar differences between G-quadruplex-forming and mutant oligonucleotides were obtained for Topo III binding to 21G and S310 oligonucleotides (Figure 1B). The IC50s for competition with oligonucleotides that cannot form G-quadruplex was 4.3 to 10.1-fold lower than for G-quadruplex forming oligonucleotides in these experiments (Figure 1B), indicating that Topo III prefers single-stranded oligonucleotides relative to G-quadruplex forming oligonucleotides.
###end p 34
###begin title 35
Topo III preferentially binds to single-stranded oligonucleotides when compared to G-quadruplex-forming sequences.
###end title 35
###begin p 36
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 172 192 172 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Material and Methods</xref>
###xml 313 315 309 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 574 581 570 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
###xml 638 639 632 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
A, Competition experiment for Topo III (50 nM) binding to [32P]-labeled 24C oligonucleotide (20 nM) in the presence of either unlabeled Pu22myc or Pu22mu (see sequences in Material and Methods) at the indicated concentrations (in microM). B, Quantification of the competition experiments for Topo III binding to [32P]-labeled S310 (top), 21G (middle), and 24C (bottom) oligonucleotides (at 20 nM) with increasing concentrations (1 to 1000 nM) of unlabeled 21G (closed circles), 21Gmu (open circles), Pu22myc (closed triangles), and Pu22mu (open triangles) oligonucleotides. Results correspond to the mean +/- SD of three determinations. f0 is the initial fraction of DNA bound to Topo III and f the fraction of DNA bound to Topo III at a determined concentration of the competitor.
###end p 36
###begin title 37
Telomestatin inhibits Topo III binding to the telomeric G-overhang
###end title 37
###begin p 38
###xml 170 192 170 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Streptomyces annulatus</italic>
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Rosu1">[12]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Shinya1">[14]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Ambrus1">[45]</xref>
###xml 511 520 511 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g002">Figure 2A</xref>
###xml 631 633 623 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 768 777 756 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g002">Figure 2B</xref>
###xml 863 865 851 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 923 925 911 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 939 954 923 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g003">Figure 3A and B</xref>
###xml 1122 1126 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Pennarun1">[17]</xref>
###xml 1128 1132 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Brassart1">[46]</xref>
###xml 170 192 <span type="species:ncbi:1892">Streptomyces annulatus</span>
We next determined whether ligands that stabilize G-quadruplex formation interfere with the binding of Topo III to the telomeric G-strand. Telomestatin was isolated from Streptomyces annulatus and potently and selectively binds to and stabilizes telomeric G-quadruplexes [12]-[14]. In these experiments, we used the Wt26 oligonucleotide previously shown to form a G-quadruplex [45]. In the presence of telomestatin, we observed a strong inhibition of Topo III-Wt26 complex as detected by bandshift experiments (Figure 2A). Slight inhibition was observed at 0.03 microM telomestatin and no complex was observed at 0.1 microM; the IC50 was 60 nM. In contrast, telomestatin (up to 10 microM) had no effect on Topo III binding to the single-stranded oligonucleotide S310 (Figure 2B). Telomestatin efficiently inhibited Topo III binding to G-quadruplex forming 21G (IC50 equal to 300 nM) but not to the mutant sequence 21Gmu (IC50 >10 microM) (Figure 3A and B). We obtained similar results using other G-quadruplex ligands such as the pyridine dicarboxamide derivative 360A and the steroid derivative funtumine guanylhydrazone [17], [46] (results not shown). We concluded that the stabilization of the G-quadruplex structure by specific ligands such as telomestatin efficiently impaired Topo III binding.
###end p 38
###begin title 39
Telomestatin inhibits Topo III and POT1 binding to telomeric G-overhangs.
###end title 39
###begin p 40
A, Bandshift assay using purified Topo III (50 nM) and [32P]-labeled Wt26 in the presence of the indicated concentrations of telomestatin. B, Bandshift assay using purified Topo III (50 nM) and [32P]-labeled S310 (20 nM) in the presence of the indicated concentrations of telomestatin. C, Bandshift assay using POT1 (30 nM) and [32P]-labeled Wt26 (20 nM) in the presence of the indicated concentrations of telomestatin. Telomestatin inhibits Topo III and POT1 binding to Wt26, which forms a G-quadruplex, but not to S310, which does not.
###end p 40
###begin title 41
Inhibition of Topo III binding to telomeric sequence by telomestatin is due to G-quadruplex formation.
###end title 41
###begin p 42
A, Bandshift assay of purified Topo III (50 nM) to [32P]-labeled 21G (20 nM) in the presence of the indicated telomestatin concentrations. B, Bandshift assay of purified Topo III (50 nM) to [32P]-labeled 21Gmu (20 nM) in the presence of the indicated telomestatin concentrations. Telomestatin had no effect on binding of Topo III to the telomeric mutant sequence 21Gmu, which cannot form a G-quadruplex.
###end p 42
###begin p 43
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez1">[42]</xref>
###xml 320 321 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 323 324 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 316 332 316 332 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-G<sub>3</sub>(T<sub>2</sub>AG<sub>3</sub>)<sub>7</sub>-3&#8242;</named-content>
###xml 336 338 336 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Rodriguez1">[47]</xref>
###xml 370 372 370 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 385 394 385 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g002">Figure 2C</xref>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez1">[42]</xref>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Tahara1">[48]</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez3">[49]</xref>
We previously reported that telomestatin inhibits the binding of POT1 to the telomeric G-overhang in a coupled transcription and translation assay [42]. The use of purified recombinant POT1 protein under bandshift conditions indicated that telomestatin also inhibited the binding of POT1 to longer oligonucleotides (5'-G3(T2AG3)7-3', IC50 of 500 nM [47]) and to Wt26 (IC50 of 100 nM) (Figure 2C). Interestingly, these values are in the same range that of telomestatin for inhibition of Topo III binding to telomere oligonucleotides (60-300 nM). Since telomestatin was shown to uncap POT1 from telomeres in cell culture [42], [48], [49], we speculated that telomestatin may also alter recruitment of Topo III to telomeres.
###end p 43
###begin title 44
Treatment with telomestatin reduces levels of Topo III, TRF2, and BLM and disorganizes APBs in MRC5-V1 ALT cells
###end title 44
###begin p 45
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wu3">[50]</xref>
###xml 444 453 444 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g004">Figure 4A</xref>
###xml 690 699 690 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g004">Figure 4A</xref>
###xml 862 871 862 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g004">Figure 4A</xref>
###xml 1022 1031 1022 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g004">Figure 4B</xref>
###xml 1224 1228 1220 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 1339 1350 1335 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g004">Figure 4B&amp;C</xref>
###xml 1622 1626 1618 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
Topo III co-localizes with telomeric proteins at APBs in ALT cells [39]. To examine the effects of telomestatin treatment on the recruitment of Topo III to these nuclear bodies in cultured cells, we stably transfected a YFP-tagged Topo III construct into MRC5-V1 ALT cells [39]. Using a D6 antibody directed against Topo III, it was shown that the tagged protein localizes at the same sites as does the endogenous protein ([39], [50], see also Figure 4A). Therefore, it can be used to investigate the cellular effect of telomestatin on Topo III localization. The YFP-Topo III fluorescence signal, which mostly corresponded to large nuclear foci, was decreased after telomestatin treatment (Figure 4A). The immunofluorescence signal of the D6 antibody was also decreased in telomestatin-treated cells, indicating that telomestatin alters Topo III protein levels (Figure 4A). Further analysis by western blot showed that Topo III protein levels were decreased by telomestatin treatment in a dose- and time-dependent manner (Figure 4B). After 72 hours of treatment with 2 microM telomestatin, we observed a nearly complete loss of Topo III protein (relative to actin). Since Topo III, BLM, and TRF2 form a complex in ALT cells [39], we next investigated if telomestatin treatment had an effect on the BLM and TRF2 protein levels. As shown in Figure 4B&C, the Topo III decrease was associated with a significant decrease in BLM and TRF2 protein levels, but there was not significant induction of apoptosis as measured by caspase 3 cleavage (result not shown). This suggests that, like siRNA inhibition of Topo III translation [39], telomestatin triggers Topo III/TRF2/BLM complex degradation in ALT cells.
###end p 45
###begin title 46
Effects of telomestatin on Topo III signals and Topo III/TRF2/BLM protein levels in MRC5-V1/YFP-Topo III cells.
###end title 46
###begin p 47
A, Representative images of untreated MRC5-V1/YFP-Topo III cells and cells treated with 2 microM telomestatin for 48 h; Topo III was detected by fluorescence of YFP-tagged Topo III (green) or by immunofluorescence using D6 antibody (red). Dapi staining of DNA is shown in blue. Telomestatin induced a decrease of Topo III foci number and intensity. B, Cells were treated with telomestatin (0.5 to 5 microM) for 24, 48, or 72 h and Topo III, BLM, TRF2, and actin protein levels were detected by western blot. Telomestatin induced a dose-dependent decrease in Topo III, TRF2, and BLM. C, quantification of the western blot experiment. Result were normalized relative to actin protein levels and expressed relative to control untreated cells, defined as 100%.
###end p 47
###begin p 48
###xml 519 528 515 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g005">Figure 5A</xref>
###xml 545 554 541 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g005">Figure 5B</xref>
###xml 784 792 780 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g006">Figure 6</xref>
###xml 924 932 920 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g007">Figure 7</xref>
###xml 1096 1105 1092 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g008">Figure 8A</xref>
###xml 1214 1229 1210 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g008">Figure 8A and B</xref>
###xml 1325 1334 1321 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g004">Figure 4B</xref>
To further analyze the effect of telomestatin on organization of APBs in MRC5-V1/YFP-Topo III cells, we treated cells with 2 microM telomestatin for 48 h, because these conditions measurably reduce Topo III, TRF2 and BLM protein levels but cells remain viable. This allowed us to perform nuclear localization studies by microscopy. Microscopic examination of treated cells showed important changes in the nuclear organization of YFP-Topo III at APBs. Telomestatin reduced the co-localization of YFP-Topo III with PMLs (Figure 5A) and with TRF2 (Figure 5B). Double staining with anti-TRF2 and with anti-PML antibodies allowed us to visualize these APBs components in MRC5-V1/YFP-Topo III cells. After telomestatin treatment, YFP-Topo III, TRF2, and PML were observed in separate foci (Figure 6). Similar loss of co-localization was observed between YFP-Topo III and two other factors of the shelterin complex, TIN2 and TRF1 (Figure 7 A and B). After telomestatin treatment, only 20% of YFP-Topo III co-localized with PML and TRF2 and only about 45% of YFP-Topo III co-localized with TRF1 or TIN2 (Figure 8A). Interestingly, telomestatin did not qualitatively alter the co-localization between YFP-Topo III and BLM (Figure 8A and B); however, BLM protein levels decreased after telomestatin treatment as shown by western-blot (Figure 4B), suggesting that telomestatin does not alter the interaction between these two proteins. These results indicate that the G-quadruplex ligand telomestatin decreases the amount of Topo III/BLM/TRF2 complex present in cells and disrupts the formation of APBs.
###end p 48
###begin title 49
Telomestatin induces a delocalization of Topo III from PML and TRF2.
###end title 49
###begin p 50
Representative images are of untreated MRC5-V1/YFP-Topo III cells or cells treated for 48 h with 2 microM telomestatin. A, Topo III detected by fluorescence of YFP-tagged Topo III (green) and PML detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. B, Topo III detected by fluorescence of YFP-tagged Topo III (green) and TRF2 detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. The extent of co-localization of Topo III and PML and of Topo III and TRF2 is decreased by telomestatin treatment relative to that in untreated cells.
###end p 50
###begin title 51
Co-localization of Topo III with PML and TRF2 is inhibited by telomestatin treatment.
###end title 51
###begin p 52
Representative images are of untreated MRC5-V1/YFP-Topo III cells and cells treated with 2 microM telomestatin for 48 h; YFP-tagged Topo III is shown in green, TRF2 is shown in red (detected by immunofluorescence), and PML is shown in blue (detected by immunofluorescence).
###end p 52
###begin title 53
Telomestatin induces a de-localization of Topo III from TIN2 and TRF1.
###end title 53
###begin p 54
Representative images are of untreated MRC5-V1/YFP-Topo III cells or cells treated for 48 h with 2 microM telomestatin. A, Topo III was detected by fluorescence of YFP-tagged Topo III (green) and TIN2 was detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. B, Topo III was detected by fluorescence of YFP-tagged Topo III (green) and TRF1 was detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. The amount of co-localization between Topo III and TIN2 or Topo III and TRF1 observed in untreated cells was decreased by telomestatin treatment.
###end p 54
###begin title 55
Telomestatin induces a delocalization of Topo III from PML and shelterin components but not from BLM.
###end title 55
###begin p 56
###xml 225 232 221 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Results</xref>
MRC5-V1/YFP-Topo III cells were left untreated or were treated for 48 h with 2 microM telomestatin. A, Quantification of the co-localization between Topo III and PML, TRF2, TRF1, TIN2, and BLM in untreated and treated cells. Results are expressed as the relative percentage of Topo IIIalpha foci that co-localize with PML, TRF2, TRF1, TIN2, or BLM foci and were determined by analysis of more than 50 nuclei. B, Topo III was detected by fluorescence of YFP-tagged Topo III (green) and BLM was detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. The co-localization of Topo III and BLM was not altered by telomestatin treatment.
###end p 56
###begin p 57
###xml 256 265 256 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006919.s001">Figure S1</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
Co-immunoprecipitation experiments were also performed to study whether the interaction of TRF2 or BLM with Topo III is altered by telomestatin treatment. In the complex precipitated by the Topo III D6 antibody, we detected TRF2 and BLM by immunoblotting (Figure S1 and [39]). After 48 hours of treatment with 2 microM telomestatin, we observed a nearly complete loss of TRF2 protein associated with Topo III. In contrast, BLM associated with Topo III is not affected by telomestatin treatment. These results confirm the immunofluorescence observations.
###end p 57
###begin title 58
Telomestatin induces a massive DNA damage response at telomeres in ALT cells
###end title 58
###begin p 59
###xml 357 361 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-dAddadiFagagna1">[51]</xref>
###xml 487 502 475 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g009">Figure 9A and B</xref>
###xml 1102 1111 1070 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g009">Figure 9C</xref>
###xml 1284 1293 1252 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g010">Figure 10</xref>
###xml 1553 1557 1521 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Douarre1">[41]</xref>
###xml 1559 1563 1527 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez2">[44]</xref>
###xml 1565 1569 1533 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Brassart1">[46]</xref>
To further determine whether telomestatin-induced ABP disruption affected telomere integrity, we tested MRC5-V1/YFP-Topo III cells for DNA damage that co-localized with telomeres. Telomere dysfunction-induced foci (TIFs) can be detected due to the presence of gamma-H2AX, a phosphorylated variant of histone 2A that associates with DNA double-strand breaks [51]. Cells treated with 2 microM telomestatin for 48 h were analyzed for gamma-H2AX-containing foci that co-localized with TRF1 (Figure 9A and B). There was a background level of gamma-H2AX foci in untreated MRC5-V1/YFP-Topo III cells of 14+/-6 foci/nucleus; only 8% (+/-2%) of these foci co-localized with TRF1. In the presence of telomestatin, we observed an increased number of gamma-H2AX foci to 68+/-4 foci/nucleus and almost half co-localized with TRF1 (46+/-4%), suggesting that telomestatin triggers a DNA damage response that mostly takes place at telomeres. However, the analysis of treated cells foci that contain both YFP-Topo III and gamma-H2AX indicated that most of the DNA damage response was not associated with Topo III foci (Figure 9C). We then evaluated the amount of G-overhang telomeric DNA signal in MRC5-V1/YFP-Topo III cells after treatment with telomestatin using solution hybridization experiments (Figure 10). A significant reduction of the hybridization was observed in telomestatin-treated cells (40% of the signal observed in untreated cells). This is in agreement with other reports where telomestatin alters telomeric G-overhang in telomerase-positive cell lines[41], [44], [46]. Together, these results indicate that telomestatin induces a massive DNA damage response at telomeres.
###end p 59
###begin title 60
DNA damage response after telomestatin treatment of MRC5-V1/YFP-Topo III cells.
###end title 60
###begin p 61
###xml 218 225 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Results</xref>
A, Cells treated for 48 h with 2 microM telomestatin or left untreated were examined for gamma-H2AX foci (green) that co-localized with TRF1 (red). B, Quantification of the DNA damage foci that co-localized with TRF1. Results are expressed as the percentage relative to gamma-H2AX foci number and were determined by analysis of more than 50 nuclei. C, Cells treated for 48 h with 2 microM telomestatin or left untreated were examined for gamma-H2AX foci (red) that co-localized with YFP-Topo III (green). In the magnification at the bottom the co-localization between gamma-H2AX and Topo III is indicated by arrows.
###end p 61
###begin title 62
Effect of telomestatin on G-overhang signal.
###end title 62
###begin p 63
###xml 244 245 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 439 446 439 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Results</xref>
A, DNA was extracted from untreated MRC5-V1/YFP-Topo III cells or cells treated for 48 h with telomestatin at indicated concentrations. The G-overhang signal was evaluated by non-denaturing solution hybridization with a telomeric probe (AATCCC)4. The gel was also stained with ethidium bromide. B, Quantification of the experiment presented in A. The G-overhang hybridization signal was normalized relative to the ethidium bromide signal. Results are expressed as the percentage of G-overhang signal in control untreated cells, which was defined as 100%.
###end p 63
###begin title 64
Discussion
###end title 64
###begin p 65
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-DeCian2">[15]</xref>
###xml 521 524 521 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Riou1">[8]</xref>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gowan1">[16]</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Pennarun1">[17]</xref>
###xml 538 542 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Kim2">[52]</xref>
Telomestatin binds specifically to G-quadruplex structures. In cells with telomerase activity, this binding results in telomere uncapping and leads to the G-overhang degradation and the release of telomeric proteins (POT1 and/or TRF2). Telomere uncapping is associated with a DNA damage response on a subset of telomere ends (for a recent review, see [15]). Little was known about the effect of telomestatin or other G-quadruplex ligands in telomerase-negative ALT cell lines, except that cell proliferation is inhibited [8], [16], [17], [52]. The results discussed here indicate that telomestatin induces G-overhang degradation in MRC5-V1/YFP-Topo III cells, an effect also observed in another ALT cell line, WI38-VA13 cells (result not shown). Our data suggest that alteration of the conformation or length of the telomeric G-overhang is a relevant marker for telomestatin activity in both telomerase positive and ALT cells.
###end p 65
###begin p 66
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Gomez3">[49]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wu4">[53]</xref>
###xml 425 428 425 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Huppert1">[4]</xref>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Wu4">[53]</xref>
Interestingly, telomestatin provoked a massive DNA damage response at telomeres in ALT cells, a result that contrasts with previous finding for this compound in telomerase-positive cell lines where only a small fraction of DNA damage foci corresponded to TIFs [49], [53]. Either telomestatin-induced DNA damage mostly takes place in extra-telomeric regions where potential G-quadruplex forming sequences have been identified [4] or the G-quadruplexes stabilized by telomestatin may be tightly regulated in telomeric regions during telomere replication. Specific G-quadruplex resolvases may repair these G-quadruplex structures to avoid replication blocks and DNA damage accumulation. For example, the FANCJ helicase suppresses the DNA damage response induced by telomestatin in telomerase-positive cells [53].
###end p 66
###begin p 67
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 409 418 409 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g011">Figure 11</xref>
###xml 642 646 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Zhong1">[54]</xref>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Jiang1">[55]</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Draskovic1">[56]</xref>
The massive DNA damage response at telomeres in ALT cells after telomestatin treatment is accompanied by depletion of the Topo III/BLM/TRF2 complex and by telomere uncapping. These are the same effects observed after Topo III depletion by siRNA in ALT cells [39]. Telomestatin treatment also disrupted APBs, as evidenced by the segregation of Topo III, PML, and other shelterin components into separate foci (Figure 11). A close linkage between the formation of APBs, the presence of proteins from the shelterin complex and telomere maintenance by recombination has been suggested, although their structural organization is poorly understood [54], [55]. These specialized bodies contain recombination proteins that are thought to support the processes that maintain telomere length in the absence of telomerase activity. Recent evidence indicates that APBs provide a platform (called telomere clusters) where post-replicative telomere recombination intermediates are resolved [56]. These structures may maintain a spatio-temporal organization of telomeres needed for the completion of these reactions. Our data are consistent with a redistribution of unprotected telomere ends due to the absence of the telomere bouquet after telomestatin treatment.
###end p 67
###begin title 68
Model for the action of telomestatin in ALT cells.
###end title 68
###begin p 69
###xml 927 935 927 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g006">Figure 6</xref>
Short telomeres to be elongated are present in the APB platform and capped with proteins from the shelterin complex (Sh), including TRF1, TRF2, TIN2, TPP1, hRAP1 and POT1. The APBs also contains PML protein and proteins from the RTR complex (RTR), including Topo III, BLM, RMI1 and RMI2. Other recombination factors are not represented for sake of clarity. Telomere elongation takes place after homologous recombination (strand invasion); a possible mechanism for the resolution of the double Holliday junction occurring at the end of the recombination process involves Topo III/BLM recruitment by TRF2 at telomeres. In the presence of telomestatin, G-quadruplex stabilization induces APB disruption, which is a phenocopy of the siRNA-mediated Topo III deficiency, together with Topo III, BLM and TRF2 depletion, exposure of telomere ends to DNA damage (uncapping) and G-overhang degradation. A magnification of the image from Figure 6 is presented to illustrate the modification of the colocalization between PML, Topo III and TRF2.
###end p 69
###begin p 70
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Jiang1">[55]</xref>
###xml 321 329 321 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The mechanistic details of the telomestatin-induced APB disruption are unclear. The depletion of several components of the shelterin complex, including TRF1, TRF2, TIN2 and RAP1 was previously shown to reduce formation of APBs [55]. Because telomestatin impairs the binding of POT1 and Topo III to the telomeric G-strand in vitro, the simplest explanation is that telomestatin disrupts the interactions to telomeres of telomere-binding proteins, inhibiting correct assembly of proteins on the APB platform. Although TRF2 does not directly bind to the telomeric G-overhang, G-quadruplex stabilization may induce indirect structural alterations at telomere ends or during replication, leading to the release and depletion of TRF2.
###end p 70
###begin p 71
###xml 133 136 133 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Palm1">[1]</xref>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Amiard1">[37]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Fouche1">[57]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-TemimeSmaali1">[39]</xref>
###xml 801 810 801 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006919-g011">Figure 11</xref>
Several pieces of evidence indicate that TRF2 affects telomere structure and represses homologous recombination events at the t-loop [1]. The N-terminal domain of TRF2 was recently reported to introduce a torsional stress in telomeric DNA, to promote strand invasion into duplex DNA and to bind to Holliday Junction structures [37], [57]. We have proposed that Topo III might play a general role in ALT telomere physiology by resolving TRF2-mediated topological intermediates to modulate the t-loop formation or to modulate recombination processes [39]. It is likely that Topo III, which is essentially a nicking-closing enzyme that recognizes a single-stranded DNA region, catalyzes the resolution of the D-loop formed at t-loop or the double-Holliday junctions formed during telomere recombination (Figure 11).
###end p 71
###begin p 72
###xml 164 172 164 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The G-quadruplex stabilization by telomestatin may interfere with t-loop formation/dissolution or with Holliday junction resolution at telomere ends. In agreement, in vitro experiments indicated that telomestatin inhibited the strand invasion reaction of a G-strand oligonucleotide into a telomeric duplex suggesting that the ligand is able to block the t-loop formation (JF Riou, unpublished results). The specific difference between ALT cells and telomerase-positive cells is due to the respective presence or absence of APBs where recombination takes place. Therefore, the inhibition of the double-Holliday junction resolution by telomestatin might be more deleterious for telomere capping than the inhibition of the t-loop formation/resolution. However we cannot exclude the possibility that the resolution of t-loop formation in ALT cells represents a critical process. Our data provides a possible clue to the important effects of telomestatin at telomeres in ALT cells and further experiments aiming to determine whether Topo III controls recombination at telomeres in mammalian cells or results from the indirect loss of TRF2 triggered by the telomestatin treatment would be of great interest.
###end p 72
###begin p 73
In conclusion, our results show that the G-quadruplex ligand telomestatin induces a telomere dysfunction in ALT cells, associated with APBs disruption and Topo III/BLM/TRF2 complex depletion. This emphasizes the interest of G-quadruplex ligands as potential therapeutics in tumor cells with alternative telomere maintenance mechanism.
###end p 73
###begin title 74
Supporting Information
###end title 74
###begin p 75
###xml 307 310 303 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006919-Palm1">[1]</xref>
###xml 325 326 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 802 823 794 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 230 236 <span type="species:ncbi:9986">rabbit</span>
Topo III/TRF2 complex is impaired in MRC5V1/YFP-Topo III cells treated with 2 microM telomestatin for 48 h. In contrast, Topo III/BLM complex is not modified by telomestatin treatment. Co-Immunoprecipitation was performed with D6 rabbit polyclonal antibody directed against Topo III as described previously [1]. Briefly, 2x107 cells were lysed using RIPA buffer supplemented with 330 mM NaCl. The extract was precleared by Protein G Sepharose 4 Fast Flow and was mixed overnight with D6 anti-Topo III antibody. 100 microl of protein G-Sepharose beads were added to each sample, and beads were collected by centrifugation and washed three times with PBS buffer, eluted with Laemmli loading buffer, and analyzed by immunoblotting with the indicated antibodies directed against TRF2, BLM or Topo III (see Materials and Methods).
###end p 75
###begin p 76
(0.09 MB PDF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
We thank A. Londono-Vallejo, Y. Pommier, D. Gomez and members of the "SANTe" team for helpful scientific discussions and comments on the manuscript.
###end p 78
###begin title 79
References
###end title 79
###begin article-title 80
How shelterin protects Mammalian telomeres.
###end article-title 80
###begin article-title 81
Telomeres and their control.
###end article-title 81
###begin article-title 82
Telomere uncapping and alternative lengthening of telomeres.
###end article-title 82
###begin article-title 83
Hunting G-quadruplexes.
###end article-title 83
###begin article-title 84
A hitchhiker's guide to G-quadruplex ligands.
###end article-title 84
###begin article-title 85
###xml 14 19 <span type="species:ncbi:9606">human</span>
Inhibition of human telomerase by a G-quadruplex-interactive compound.
###end article-title 85
###begin article-title 86
Telomerase: a therapeutic target for the third millennium?
###end article-title 86
###begin article-title 87
Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands.
###end article-title 87
###begin article-title 88
G-quadruplex interacting agents targeting the telomeric G-overhang are more than simple telomerase inhibitors.
###end article-title 88
###begin article-title 89
Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
###end article-title 89
###begin article-title 90
Reevaluation of telomerase inhibition by quadruplex ligands and their mechanisms of action.
###end article-title 90
###begin article-title 91
###xml 42 47 <span type="species:ncbi:9606">human</span>
Telomestatin-induced stabilization of the human telomeric DNA quadruplex monitored by electrospray mass spectrometry.
###end article-title 91
###begin article-title 92
###xml 87 92 <span type="species:ncbi:9606">human</span>
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex.
###end article-title 92
###begin article-title 93
###xml 48 69 <span type="species:ncbi:1892">Streptomyces anulatus</span>
Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus.
###end article-title 93
###begin article-title 94
Targeting telomeres and telomerase.
###end article-title 94
###begin article-title 95
Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes.
###end article-title 95
###begin article-title 96
###xml 72 77 <span type="species:ncbi:9606">human</span>
Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands.
###end article-title 96
###begin article-title 97
Inhibition of the Bloom's and Werner's syndrome helicases by G- quadruplex interacting ligands.
###end article-title 97
###begin article-title 98
Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2.
###end article-title 98
###begin article-title 99
ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle.
###end article-title 99
###begin article-title 100
###xml 33 38 <span type="species:ncbi:9606">human</span>
Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
###end article-title 100
###begin article-title 101
The RecQ helicase-topoisomerase III-Rmi1 complex: a DNA structure-specific 'dissolvasome'?
###end article-title 101
###begin article-title 102
More complexity to the Bloom's syndrome complex.
###end article-title 102
###begin article-title 103
The Bloom's syndrome helicase suppresses crossing over during homologous recombination.
###end article-title 103
###begin article-title 104
BLAP75/RMI1 promotes the BLM-dependent dissolution of homologous recombination intermediates.
###end article-title 104
###begin article-title 105
A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75.
###end article-title 105
###begin article-title 106
Binding and activation of DNA topoisomerase III by the Rmi1 subunit.
###end article-title 106
###begin article-title 107
BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome.
###end article-title 107
###begin article-title 108
RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability.
###end article-title 108
###begin article-title 109
ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation.
###end article-title 109
###begin article-title 110
Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis.
###end article-title 110
###begin article-title 111
Possible association of BLM in decreasing DNA double strand breaks during DNA replication.
###end article-title 111
###begin article-title 112
Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage.
###end article-title 112
###begin article-title 113
Cellular roles of DNA topoisomerases: a molecular perspective.
###end article-title 113
###begin article-title 114
###xml 22 29 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Structural studies of E. coli topoisomerase III-DNA complexes reveal a novel type IA topoisomerase-DNA conformational intermediate.
###end article-title 114
###begin article-title 115
How telomeres are replicated.
###end article-title 115
###begin article-title 116
A topological mechanism for TRF2-enhanced strand invasion.
###end article-title 116
###begin article-title 117
Involvement of topoisomerase III in telomere-telomere recombination.
###end article-title 117
###begin article-title 118
Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.
###end article-title 118
###begin article-title 119
###xml 37 42 <span type="species:ncbi:9606">human</span>
Purification and characterization of human DNA topoisomerase IIIalpha.
###end article-title 119
###begin article-title 120
Overexpression of Bcl-2 is associated with apoptotic resistance to the G-quadruplex ligand 12459 but is not sufficient to confer resistance to long-term senescence.
###end article-title 120
###begin article-title 121
###xml 143 148 <span type="species:ncbi:9606">human</span>
The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells.
###end article-title 121
###begin article-title 122
Stabilization of the c-myc gene promoter quadruplex by specific ligands inhibitors of telomerase.
###end article-title 122
###begin article-title 123
Interaction of telomestatin with the telomeric single-strand overhang.
###end article-title 123
###begin article-title 124
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human telomeric sequence forms a hybrid-type intramolecular G-quadruplex structure with mixed parallel/antiparallel strands in potassium solution.
###end article-title 124
###begin article-title 125
###xml 85 90 <span type="species:ncbi:9606">human</span>
A new steroid derivative stabilizes g-quadruplexes and induces telomere uncapping in human tumor cells.
###end article-title 125
###begin article-title 126
A Novel Small Molecule That Alters Shelterin Integrity and Triggers a DNA-Damage Response at Telomeres.
###end article-title 126
###begin article-title 127
G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells.
###end article-title 127
###begin article-title 128
###xml 100 105 <span type="species:ncbi:9606">human</span>
Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells.
###end article-title 128
###begin article-title 129
The Bloom's syndrome gene product interacts with topoisomerase III.
###end article-title 129
###begin article-title 130
A DNA damage checkpoint response in telomere-initiated senescence.
###end article-title 130
###begin article-title 131
The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures.
###end article-title 131
###begin article-title 132
FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability.
###end article-title 132
###begin article-title 133
Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres.
###end article-title 133
###begin article-title 134
Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.
###end article-title 134
###begin article-title 135
Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
###end article-title 135
###begin article-title 136
###xml 90 96 90 96 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTAGGG</named-content>
The basic domain of TRF2 directs binding to DNA junctions irrespective of the presence of TTAGGG repeats.
###end article-title 136
###begin p 137
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 137
###begin p 138
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by the "Ligue Nationale contre le Cancer, Equipe Labellisee". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 138

